To diagnose heart conditions including heart attacks and heart rhythm disturbances, clinicians typically rely on 12-lead electrocardiograms (ECGs) -- complex arrangements of electrodes and wires ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that ...
DiaCardia enables accurate prediabetes/diabetes screening using either 12-lead or single-lead electrocardiogram (ECG) data, demonstrating potential for scalable and accessible testing devices.
Pre-screening is crucial for athletes to reduce the risk of sudden cardiac death (SCD). However, 12 lead ECG screening alone is insufficient to prevent SCD. Objective This study aims to determine the ...
Hosted on MSN
HeartBeam (NASDAQ: BEAT) secures FDA 510(k) clearance for 12-lead ECG synthesis software following successful appeal
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for ...
HeartBeam, Inc. (BEAT) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results